Nitinotes is a privately-held medical device company based in caesarea Israel. Its flagship product is the endozip™, a novel robotic gastroscopic solution for safer, simpler GI suturing. Backed by clinical success and prominent KOLs, Nitinotes’ endozip proceedure provides an effective, minimally-invasive solution to class 1 and 2 obesity patients, for the majority of whom gold-standard bariatric surgery is uncovered and/or inadvisable.
Location: Israel, Haifa District, Caesarea
Employees: 1-10
Total raised: $7.1M
Founded date: 2014
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.05.2020 | - | $7.1M | - |
Mentions in press and media 3
| Date | Title | Description |
| 09.07.2026 | Nitinotes Announces First Commercial EndoZip™ Cases in Germany | Commercial adoption continues to accelerate across Europe as leading physicians introduce EndoZip™ into one of the region’s largest obesity treatment markets. CAESAREA, ISRAEL, July 9, 2026 /EINPresswire.com/ -- Nitinotes Ltd., developer of... |
| 10.05.2020 | Nitinotes announces closing of an internal $7.1M series A1 funding | Bringing the total funds raised by Nitinotes to $11.5M, this funding will go towards finalizing the development of the Endozip automated suturing system, and execution of a multi-center pilot study in the EU. |
| - | NitiNotes | “Nitinotes is a clinical stage company developing a revolutionary treatment for obesity.Its flagship product, the EndoZip™, simplifies and speeds up endoscopic gastroplasty procedures, offering a widely available, minimally invasive and eff... |